Glucocorticoid Mimetics Selective Receptor Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current glucocorticoid drugs have significant anti-inflammatory effects but are associated with severe side effects such as fluid and electrolyte imbalances, weight gain, hypertension, and increased risk of diabetes, due to their non-selective activation of glucocorticoid receptor pathways, which also mediate metabolic and cardiovascular effects.
Innovation Solution
Development of novel compounds, such as those represented by Formula (IA), which selectively interact with the glucocorticoid receptor to dissociate transactivation and transrepression pathways, reducing side effects while maintaining anti-inflammatory efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If glucocorticoid drugs are used to achieve anti-inflammatory effects, then inflammatory and immune disorders are treated effectively, but severe side effects such as fluid and electrolyte imbalances, weight gain, hypertension, and increased risk of diabetes occur
Solution Approach 1:
The patent applies segmentation by dividing the glucocorticoid receptor pathways into two distinct functional pathways: transactivation (mediating side effects) and transrepression (mediating anti-inflammatory effects). The invention develops compounds that selectively modulate one pathway while sparing the other, thereby resolving the contradiction between efficacy and side effects by treating the two functions separately rather than as a unified action.
Solution Approach 2:
The patent applies local quality by creating compounds with selective affinity for specific glucocorticoid receptor conformations or pathways. The compounds are designed to interact preferentially with the transrepression pathway while having minimal effect on the transactivation pathway, thereby achieving localized modulation of receptor function to maintain anti-inflammatory benefits while reducing harmful metabolic effects.
2Reliability
If glucocorticoids activate glucocorticoid receptor pathways, then anti-inflammatory effects are achieved, but metabolic and cardiovascular side effects occur due to non-selective activation
Solution Approach 1:
The patent segments the glucocorticoid receptor activation into distinct transactivation and transrepression pathways, developing compounds that selectively engage the transrepression pathway (responsible for anti-inflammatory effects) while avoiding transactivation (responsible for metabolic and cardiovascular side effects). This selective pathway engagement resolves the contradiction by decoupling therapeutic benefit from harmful effects.
Solution Approach 2:
The patent applies parameter changes by modifying the chemical structure of glucocorticoid compounds to alter their binding characteristics and pathway selectivity. By changing molecular parameters such as substituent groups and stereochemistry, the compounds achieve preferential activation of the transrepression pathway while minimizing transactivation, thereby reducing metabolic and cardiovascular side effects while maintaining anti-inflammatory efficacy.
Data Source
AI summary
Compounds of Formula (IA) and (IB)wherein R1, R2, R3, A, B, C, D, and E are as defined herein, or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.